Low-dose methotrexate combined with superficial X-ray in the treatment of folliculotropic mycosis fungoides: A case report

Sir,

According to the World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC), folliculotropic mycosis fungoides (FMF) is categorized as a variant of mycosis fungoides (MF) because of its distinctive clinicopathologic features. Skin findings include grouped follicular or acniform papules, such as clustered comedones, nodulocystic lesions, pustules, milia, as well as indurated plaques or tumors. Representative skin lesions typically involve the head and neck, especially the eyebrow, showing plaques and alopecia with severe pruritus. Histopathologically, the follicular epithelium is infiltrated with atypical lymphocytes, with relative epidermal sparing. This variant is associated with a worse prognosis than classical mycosis fungoides because of its resistance to conventional therapies.

A 51-year-old female was admitted to our outpatient department, with a 10-year history of erythematous papules and plaques associated with severe pruritus. Clinical examination revealed alopecia and erythematous, scaly papules, and plaques scattered on the head, neck, trunk, and extremities [Figures 1 and 2]. Alopecia only involved the scalp. Lesions of the head and neck showed infiltration and erosion [Figure 1]. There was no palpable lymphadenopathy or hepatosplenomegaly. Laboratory investigations such as blood count, urinalysis, biochemical profile, serum protein electrophoresis levels, and bone marrow aspiration were all within normal limits. Imaging studies including chest X-ray, computed tomographic scan, and echocardiography were normal. Skin biopsy revealed intrafollicular or perifollicular infiltration of atypical lymphocytes with minimal epidermal involvement [Figure 3]. In addition, intrafollicular mucin deposits [Figure 4] were observed on Alcian blue stain [Figure 5]. The overlying epidermis showed focal epidermotropism, and few lymphocytes showed mild cytological atypia [Figure 6]. Immunohistochemically, the atypical lymphocytes were positive for CD2, CD3, CD4, CD7, and CD8, with a normal CD4:CD8 ratio, which favored T-cell proliferation. Staining for CD20, CD79a, CD30, and CD68 showed negative results. T-cell receptor

Figure 1: Erythematous papules and plaques, scales, and erosion involving the face and neck

Figure 2: Erythematous papules, plaques, and scales scattered on the trunk
gamma (TCR gamma) rearrangement confirmed a monoclonal proliferation of the atypical T lymphocytes. Considering the clinical and histopathological examination, diagnosis of stage IIA folliculotropic mycosis fungoides was made.

Initially, the patient was treated with interferon α-2b, isotretinoin, nitrogen mustard, and psoralen-UVA for 1 month, resulting in minimal improvement. Subsequently, methotrexate was added for 1 month, which resulted in an excellent response [Table 1]. The initial dose of methotrexate was 10 mg per week and the maximal dose was 15 mg per week. Most lesions on the trunk and extremities disappeared after these treatments. However, some persistent plaques remained on the head and neck. The patient was then treated with a combination of methotrexate 10 mg weekly plus superficial X-ray (100 kV, 400 cGy–500 cGy, a total dose of 40 Gy for 9 cycles) per week for 3 months [Table 2], which resulted in dramatic remission [Figure 7]. The patient continues to be in clinical remission after 10 months.

Folliculotropic mycosis fungoides, a distinct variant of mycosis fungoides, is characterized by the presence of folliculotropic infiltrates, that often spare the epidermis and preferentially involve the head and neck area. It is associated with a worse prognosis than classical mycosis fungoides, due to resistance to conventional therapies such as isotretinoin, methotrexate, PUVA, and interferon. In our patient, most lesions responded well to conventional therapies, except for persistent lesions on the head and neck area. Agar et al. reported that a patient with

| Therapy                  | Dose           | Duration | Side effects |
|--------------------------|----------------|----------|--------------|
| Interferon α-2b          | 300 IU 3 times/qw | 2 weeks  | Fever        |
| Isotretinoin             | 10 mg BID-TID  | 5 months | Dry mouth    |
| Methotrexate             | 10-15 mg qw    | 4 months | None         |
| Nitrogen mustard         | Local application 2 times/qd | All the time | None |
| Psoralen and ultraviolet A | 3 times/qw  | 3 months | None         |

Figure 3: Intrafollicular and perifollicular infiltration with atypical lymphocytes and minimal epidermal involvement (H and E, ×100)

Figure 4: Follicular infiltration with mucin deposition (H and E, ×100)

Figure 5: Alcian blue staining showing intrafollicular mucin (×200)

Figure 6: Epidermis showing focal epidermotropism and few lymphocytes showing mild cytological atypia (H and E, ×200)
localized thick plaques on the head, was treated successfully with superficial radiotherapy. Demirkesen et al. reported that patients with folliculotropic mycosis fungoides, who received more aggressive and combined treatments such as PUVA, methotrexate, interferon, and radiotherapy, achieved a higher survival rate. Kelly et al. reported that patients in stages I–III, who were treated with topical Carmustine as monotherapy, with or without an added systemic agent demonstrated a high degree of response. In addition, a 16-year-old patient who presented with a single, firm, well-circumscribed erythematous infiltrated plaque over the forehead was successfully treated with local electron beam therapy. Since the persistent lesions were localized in our patient, we chose X-ray as an additional treatment. She showed dramatic remission—a fact which may help direct future treatment guidelines of this condition. We were unable to find previous reports of the combination treatment of methotrexate with superficial X-ray in our literature search.

This regimen—methotrexate with superficial X-ray therapy—may be a new viable therapeutic option for recalcitrant mycosis fungoides, especially the folliculotropic variant.

**Acknowledgment**

The authors would like to thank the pathology department of Guang Dong Provincial Dermatology Hospital for their contribution to the histopathology images and thank Tiange Zhang for his help of revision.

**Declaration of patient consent**

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given her consent for her images and other clinical information to be reported in the journal. The patient understands that name and initial will not be published and due efforts will be made to conceal identity, but anonymity cannot be guaranteed.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

Yanan Jiang, Ruzeng Xue, Weijia Wang, Yongfeng Chen

1,2, Graduate School, Guangdong Medical University, Zhanjiang, 2, Dermatology Department, Guang Dong Provincial Dermatology Hospital, Guangzhou, China.

**Correspondence:** Prof. Yongfeng Chen, Guang Dong Provincial Dermatology Hospital, No 2, LuJing Road, Guangzhou, China.

**E-mail:** gdcyf@163.com

**Table 2: Treatment plan used from September 2015 November 2016**

| Month        | 1   | 2   | 3   | 4   | 5   | 6-15 |
|--------------|-----|-----|-----|-----|-----|------|
| Interferon a-2b | a   |     |     |     |     |      |
| Isotretinoin mg/day | 30  | 20  | *   | *   | *   | b    |
| Methotrexate mg/qw | 10−15 | 10  | *   | *   | c   |      |
| Nitrogen mustard | d   | *   | *   | *   | *   |      |
| Psoralen and ultraviolet A | c   | *   | *   | *   |      |      |
| Superficial X-ray |      | f   | *   | *   | g   |      |

*Treatment is the same as the previous month, *Three-million units three times a week. Because of fever, interferon a-2b was stopped after 2 weeks, *During the 10-month (6th-15th month) follow-up, isotretinoin was used intermittently, *During the 10 months (6th-15th month) follow-up, there was mild recurrence. MTX was used discontinuously, *Nitrogen mustard (concentration: 0.02%): External application, *Psoralen-UVA: Three times a week, *Superficial X-ray (100 kV, 400-500 cGy) per week, *During the 10 months (6th-15th month) follow-up, superficial X-ray was used intermittently.

References

1. Hodak E, Amitay-Laish I, Atzmony L, Prag-Naveh H, Yanickin N, Barzilai E, et al. New insights into folliculotropic mycosis fungoides (FMF): A single-center experience. J Am Acad Dermatol 2016;75:347-55.
2. Spence-Shishido A, Streicher JL, George RP, Parker SR, Lawley LP. Folliculotropic mycosis fungoides as a posttransplant lymphoproliferative disorder. Pediatrics 2015;136:e701-5.
3. Kelly M, Knechevski M, Ben-Amitai D, Feinig E, Sorin D, Hodak E. Unilesional folliculotropic mycosis fungoides: A unique variant of cutaneous lymphoma. J Eur Acad Dermatol Venereol 2016;30:25-9.
4. Demirkesen C, Esirgen G, Engin B, Songur A, Ozgu R. The clinical features and histopathological patterns of folliculotropic mycosis fungoides in a series of 38 cases. J Cutan Pathol 2015;42:22-31.
5. Agar N, Whittaker MJ. Folliculotropic mycosis fungoides (stage IIa) progressing to Sézary syndrome: A case report. Br J Dermatol 2008;159:1197-9.
6. MacArthur KM, Jariwala N, Kim EJ, Rook AH. Topical Carmustine as monotherapy or as multimodality therapy for folliculotropic mycosis fungoides. Acta Derm Venereol 2017;97:373-4.
Sir,

Drug-induced hypersensitivity syndrome, also known as drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, is a rare, severe cutaneous adverse reaction characterized by fever, rash, lymphadenopathy, eosinophilia and/or other leukocyte abnormalities, and internal organ involvement. With an estimated mortality rate of 10–20%, timely treatment of drug hypersensitivity syndrome is important. Treatment involves discontinuation of suspected causative medication, supportive care, and systemic corticosteroids. Here, we present a patient with drug hypersensitivity syndrome, who showed suboptimal response to oral corticosteroids and was subsequently treated successfully with a short course of cyclosporine therapy.

A 48-year-old man weighing 60 kg was transferred from a local community hospital history of intermittent fever and rash of one month's duration. Physical examination revealed erythematous edematous papules on the forearms and swelling of the face. The patient was diagnosed with drug-induced hypersensitivity syndrome based on the clinical presentation and laboratory findings. Despite initial treatment with oral corticosteroids, the patient's condition did not improve significantly. At that point, a short course of cyclosporine therapy was initiated, resulting in a marked improvement in the patient's symptoms.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.